Gerovital - is an anti-aging drug, already known as Gerovital-H3, it's main ingredient - procaine. This famous drug was discovered by Professor Aslan Ana of Romania. Procaine improves cell metabolism, concentration, memory, well-being, improves skin and hair condition.
Below you find a list of scientific abstracts about Gerovital.

Acute renal failure due to self-medication.
Procaine (Gerovital): no effect on the rehabilitation result in patients with back or hip disease.
Changes induced in the bioelectric activity of rat subcortical nervous structures by Gerovital H3 and Aslavital as compared to procaine.
The effects of procaine/haematoporphyrin on age-related decline: a double-blind trial.
Interference of Aslavital with the cytoenzymic changes induced by cold in the adrenal cortex of Wistar rats.
Gerovital-H3: a clinical trial as an antidepressant.
Successes in novocain therapy in the control of premature ageing (author's transl).
Hypersensitivity reactions to Gerovital.
The systemic use of procaine in the treatment of the elderly: a review.
Effects of a procaine preparation (Gerovital H3) in hospitalized geriatric patients: a double-blind study.
Procaine HCl (Gerovital H3): a weak, reversible, fully competitive inhibitor of monoamine oxidase.
Neth J Med. 1998 Jul;53(1):45-6
Acute renal failure due to self-medication.
Somsen GA, Schut NH.

A patient with rhabdomyolysis and transient renal failure due to auto injection of the procaine containing drug "Gerovital" is described. This case illustrates the hazards of self-regulated alternative treatment.

Ann Med. 1990 Jun;22(3):151-6
Procaine (Gerovital): no effect on the rehabilitation result in patients with back or hip disease.
Rissanen V, Rissanen P, Tuomisto J.
Siilinjarvi Rehabilitation Centre, Finland.

Gerovital was compared with placebo and another procaine preparation in a double blind study of 88 rehabilitation patients suffering from back or hip disease. In an open part of the study procaine from intramuscularly injected Gerovital disappeared from the plasma within 15-30 minutes. In patients treated with Gerovital or another procaine no clinical, physiological or psychological benefits were found in addition to the improvements following rehabilitation compared with placebo treatment. Clinical examination showed that the benefits of rehabilitation were similar in patients receiving Gerovital, another procaine and placebo.

Physiologie. 1988 Jul-Sep;25(3):137-49
Changes induced in the bioelectric activity of rat subcortical nervous structures by Gerovital H3 and Aslavital as compared to procaine.
Pop M, Tarba C.
University of Cluj-Napoca, Department of Biology, Romania.

Intravenous injection of Gerovital H3 and procaine (20 mg/kg b.w.) into white Wistar rats anaesthetized with nembutal (40 mg/kg b.w.) produces a constant decrease of the wave frequency, more visible at the level of the lateral hypothalamus, but also present in the midbrain reticular formation (the two subcortical nervous structures studied). The wave amplitude is also decreased, especially in the lateral hypothalamus, but the differences gradually recover, a fact more visible in the case of Gerovital H3. Aslavital has similar effects on the wave amplitude, whereas the changes produced in the wave frequency are generally more superficial and transitory. Moreover, the frequency variations in the reticular formation are opposite to those observed in the lateral hypothalamus (i.e., an increase instead of a decrease). Direct intrahypothalamic administration of the drugs (16 micrograms procaine/animal) induces a pattern of responses which is generally opposite to that observed for intravenous injection. Also, the changes produced in the lateral hypothalamus are more superficial this time. An opposition between the effects of Aslavital and of the other two drugs can be observed in this case for the wave amplitude, which is usually increased by procaine and Gerovital H3 and decreased by Aslavital. In many cases, Aslavital induces a burst of positive sharp waves reminiscent of the epileptiform abnormality. The differences observed are tentatively explained by us in terms of dose, drug composition and selective action upon different nervous structures.

Age Ageing. 1983 Nov;12(4):302-8
The effects of procaine/haematoporphyrin on age-related decline: a double-blind trial.
Hall MR, Briggs RS, MacLennan WJ, Marcer D, Robinson MJ, Everett FM.

A randomized, double-blind study of procaine/haematoporphyrin (KH3) has been carried out over two years in a selected population of healthy elderly subjects. The period of study exceeds 500 patient years. The trial population was weighted to contain a larger proportion of subjects aged over 75 years than a standard population; those receiving active KH3 had similar characteristics on entry to those receiving placebo. Over the course of two years, KH3 was shown to be an active substance in that: (a) decrement in the consolidation of new learning was prevented in the treatment group (less than 1.0%, as against 38% in the placebo group); (b) the prevalence of incontinence increased significantly in the placebo group, but not in the active group (P less than 0.05); (c) there was a significant increase in grip strength in the active treatment group (+22%, P less than 0.01 v. placebo); (d) more adverse reactions were observed on treatment with KH3 (P less than 0.005).

Morphol Embryol (Bucur). 1981 Apr-Jun;27(2):173-6
Interference of Aslavital with the cytoenzymic changes induced by cold in the adrenal cortex of Wistar rats.
Rusu VM, Vrabiescu A, Abraham AD, Puica C.

The repeated exposure to cold of 2-month- and 2-year-old rats resulted in an important depression of the activity of numerous enzymes in the adrenal cortex. The simultaneous treatment with Aslavital administered in successive doses prevented the decrease of the enzymic activity. It seems that Aslavital exerted a stimulating action on the biosynthesis processes of glucocorticoid hormones and subsequently induced the processes of acclimatization to cold in rats submitted to treatment.

J Gerontol. 1978 Jul;33(4):514-20
Gerovital-H3: a clinical trial as an antidepressant.
Olsen EJ, Bank L, Jarvik LF.
Twenty-five volunteers, all in their fifth decade or beyond, all with mild to moderate, nonpsychotic depression of at least several months' duration participated in a double-blind study of Gerovital vs placebo. There was no significant difference between the Gerovital and placebo groups; both groups showed significant improvement on self-rating as well as observer rating scales.

ZFA. 1977;32(3):267-9
Successes in novocain therapy in the control of premature ageing (author's transl)
Article in German
Zdichynec B.

A group of 173 patients with the diagnosis of systemic arteriosclerosis received a treatment with Novocain, according to the following schedule: three times a week intramusculary injections of 2% procain 5ml, that means 12 injections a month in 3--5 series. The results were very encouraging in 46% of the treated patients, in 28% a slight improvement was obtained while in 26% the state was unchanged but not worse. The treatment with Gerovital H3 according to A. Aslans method gave very good results in the treatment of diseases like: heart ischemia, systemic arteriosclerosis, predominant cerebral arteriosclerosis, arteriosclerotic Parkinsons disease; obvious results were also obtained in the treatment of psychical disturbances related to arteriosclerosis. The comparison with the control group (patients with placebo) emphasized the good results of the treatment of Aslan: Gerovital H3.

Dermatologica. 1977;154(6):367-9
Hypersensitivity reactions to Gerovital.
Forstrom L, Hannuksela M, Idanpaan-Heikkila J, Salo OP.

Procaine chloride, which was a common cause of allergic reactions in earlier years, has lost importance as a contact allergen because its use for local anesthesia has ceased. Recently, we have seen hypersensitivity reactions in three patients after the use of Gerovital, which is known to contain procaine chloride. A word of warning is warranted against indiscriminate use of Gerovital, particularly of its topical preparations.

J Am Geriatr Soc. 1977 Jan;25(1):1-19
The systemic use of procaine in the treatment of the elderly: a review.
Ostfeld A, Smith CM, Stotsky BA.

This article is a review and evaluation of the world literature on the systemic use of procaine in the treatment of the aging process and the common chronic diseases of later life. Included are data from 285 articles and books, describing treatment in more than 100,000 patients in the past 25 years. Except for a possible antidepressant effect, there is no convincing evidence that procaine (or Gerovital, of which procaine is the major component) has any value in the treatment of disease in older patients. If procaine has an antidepressant effect, there is some likelihood that this accounts for the reports of decreased complaints referable to the musculoskeletal, cardiovascular, endocrine sexual, gastrointestinal and respiratory systems.

J Am Geriatr Soc. 1975 Aug;23(8):355-9
Effects of a procaine preparation (Gerovital H3) in hospitalized geriatric patients: a double-blind study.
Zwerling I, Plutchik R, Hotz M, Kling R, Rubin L, Grossman J, Siegel B.

The effects of Gerovital H3 (a specially stabilized form of procaine hydrochloride) on geriatric psychiatric patients were assessed in a double-blind study at Bronx State Hospital. The mean age of the subjects was 73 years and the average rating for the severity of organic symptoms was "moderate." During the first six weeks of study, the patients were each given a 5-ml injection of either Gerovital or placebo (saline) intramuscularly three times a week. This dosage was doubled to 10 ml per injection during the second six weeks.Nine Gerovital and 10 control subjects completed the first six weeks; and 6 Gerovital and 7 control subjects completed the entire 12-week study. Objective rating scales were used to evaluate patients on measures of interpersonal functioning, cognitive ability, psychiatric symptoms, and urine and blood chemical findings. All subjects were assessed before treatment and at six weeks and twelve weeks of the study. Side effects were recorded at two-week intervals. On most measures the variability between subjects was quite large, whereas differences between average scores for the two groups usually were small The few significant differences showed no systematic pattern and would be expected to occur by chance alone when so many statistical comparisons are made. The overall results of this double-blind study strongly indicated that, among these hospitalized geriatric patients with organic symptoms, Gerovital H3 had no ameliorative effect on either psychologic or physiologic functioning.

Fed Proc. 1975 Jan;34(1):108-10
Procaine HCl (Gerovital H3): a weak, reversible, fully competitive inhibitor of monoamine oxidase.
MacFarlane MD.

A specially stabilized form of procaine hydrochloride (Gerovital H3) has been shown to be a more potent inhibitor of monoamine oxidase than procaine HCl itself and a weaker inhibitor of this enzyme than iproniazid. This preparation was studied to determine its mode of interaction with monoamine oxidase using purified rat brain mitochondrial monoamine oxidase as the enzyme source. Reaction velocities were determined spectrophotometrically by quantitating the rate of appearance of 4-hydroxyquinoline from kynuramine. Dilutional studies comparing the mechanism of inhibition of monoamine oxidase produced by Gerovital H3 and by ipronizid demonstrated that Gerovital H3 was a reversible inhibitor of monoamine oxidase. Analysis of studies using Lineweaver-Burk and Dixon plots revealed that Gerovital H3 was a fully competitive inhibitor of monoamine oxidase. That Gerovital H3 is a weak, reversible, competitive inhibitor of monoamine oxidase may explain the absence of adverse reactions associated with the clinical use of Gerovital H3 as compared to the severe adverse reactions that have been associated with the use of irreversible monoamine oxidase inhibitors.

on the Adriatic Coast
The Anti-Aging Fasting Program consists of a 7-28 days program (including 3 - 14 fasting days). 7-28-day low-calorie diet program is also available .
More information
    The anti-aging story (summary)
Introduction. Statistical review. Your personal aging curve
  Aging and Anti-aging. Why do we age?
    2.1  Aging forces (forces that cause aging
Internal (free radicals, glycosylation, chelation etc.) 
External (Unhealthy diet, lifestyle, wrong habits, environmental pollution, stress, poverty-change "poverty zones", or take it easy. etc.) 
    2.2 Anti-aging forces
Internal (apoptosis, boosting your immune system, DNA repair, longevity genes) 
External (wellness, changing your environment; achieving comfortable social atmosphere in your life, regular intake of anti-aging drugs, use of replacement organs, high-tech medicine, exercise)
    2.3 Aging versus anti-aging: how to tip the balance in your favour!
    3.1 Caloric restriction and fasting extend lifespan and decrease all-cause mortality (Evidence)
      Human studies
Monkey studies
Mouse and rat studies
Other animal studies
    3.2 Fasting and caloric restriction prevent and cure diseases (Evidence)
Hypertension and Stroke
Skin disorders
Mental disorders
Neurogical disorders
Asthmatic bronchitis, Bronchial asthma
Bones (osteoporosis) and fasting
Arteriosclerosis and Heart Disease
Cancer and caloric restriction
Cancer and fasting - a matter of controversy
Eye diseases
Chronic fatigue syndrome
Sleeping disorders
Rheumatoid arthritis
Gastrointestinal diseases
    3.3 Fasting and caloric restriction produce various
      biological effects. Effects on:
        Energy metabolism
Lipids metabolism
Protein metabolism and protein quality
Neuroendocrine and hormonal system
Immune system
Physiological functions
Reproductive function
Cognitive and behavioral functions
Biomarkers of aging
    3.4 Mechanisms: how does calorie restriction retard aging and boost health?
        Diminishing of aging forces
  Lowering of the rate of gene damage
  Reduction of free-radical production
  Reduction of metabolic rate (i.e. rate of aging)
  Lowering of body temperature
  Lowering of protein glycation
Increase of anti-aging forces
  Enhancement of gene reparation
  Enhancement of free radical neutralisation
  Enhancement of protein turnover (protein regeneration)
  Enhancement of immune response
  Activation of mono-oxygenase systems
  Enhance elimination of damaged cells
  Optimisation of neuroendocrine functions
    3.5 Practical implementation: your anti-aging dieting
        Fasting period.
Re-feeding period.
Safety of fasting and low-calorie dieting. Precautions.
      3.6 What can help you make the transition to the low-calorie life style?
        Social, psychological and religious support - crucial factors for a successful transition.
Drugs to ease the transition to caloric restriction and to overcome food cravings (use of adaptogenic herbs)
Food composition
Finding the right physician
    3.7Fasting centers and fasting programs.
  Food to eat. Dishes and menus.
    What to eat on non-fasting days. Dishes and menus. Healthy nutrition. Relation between foodstuffs and diseases. Functional foods. Glycemic index. Diet plan: practical summary. "Dr. Atkins", "Hollywood" and other fad diets versus medical science

Bread, cereals, pasta, fiber
Glycemic index
Meat and poultry
Sugar and sweet
Fats and oils
Dairy and eggs
Nuts and seeds
Food composition

  Anti-aging drugs and supplements
    5.1 Drugs that are highly recommended
      (for inclusion in your supplementation anti-aging program)
        Vitamin E
Vitamin C
Co-enzyme Q10
Lipoic acid
Folic acid
Flavonoids, carotenes
Vitamin B
Vinpocetine (Cavinton)
Deprenyl (Eldepryl)
    5.2 Drugs with controversial or unproven anti-aging effect, or awaiting other evaluation (side-effects)
        Phyto-medicines, Herbs
      5.3 Drugs for treatment and prevention of specific diseases of aging. High-tech modern pharmacology.
        Alzheimer's disease and Dementia
Immune decline
Infections, bacterial
Infections, fungal
Memory loss
Muscle weakness
Parkinson's disease
Prostate hyperplasia
Sexual disorders
Stroke risk
Weight gaining
    5.4 The place of anti-aging drugs in the whole
      program - a realistic evaluation
    6.1 Early diagnosis of disease - key factor to successful treatment.
      Alzheimer's disease and Dementia
Cataracts and Glaucoma
Genetic disorders
Heart attacks
Immune decline
Infectious diseases
Memory loss
Muscle weakness
Parkinson's disease
Prostate hyperplasia
Stroke risk
Weight gaining
    6.2 Biomarkers of aging and specific diseases
    6.3 Stem cell therapy and therapeutic cloning
    6.4 Gene manipulation
    6.5 Prosthetic body-parts, artificial organs
Bones, limbs, joints etc.
Heart & heart devices
    6.6 Obesity reduction by ultrasonic treatment
  Physical activity and aging. Experimental and clinical data.
        Aerobic exercises
Weight-lifting - body-building
Professional sport: negative aspects
  Conclusion: the whole anti-aging program
    9.1 Modifying your personal aging curve
      Average life span increment. Expert evaluation.
Periodic fasting and caloric restriction can add 40 - 50 years to your lifespan
Regular intake of anti-aging drugs can add 20-30 years to your lifespan
Good nutrition (well balanced, healthy food, individually tailord diet) can add 15-25 years to your lifespan
High-tech bio-medicine service can add 15-25 years to your lifespan
Quality of life (prosperity, relaxation, regular vocations) can add 15-25 years to your lifespan
Regular exercise and moderate physical activity can add 10-20 years to your lifespan
These approaches taken together can add 60-80 years to your lifespan, if you start young (say at age 20). But even if you only start later (say at 45-50), you can still gain 30-40 years

Click image
to view
    9.2 The whole anti-aging life style - brief summary 
    References eXTReMe Tracker
        The whole anti-aging program: overview

Home Contact Us ANTI-AGING GUIDE 2003